Kura Oncology (NASDAQ:KURA) Given New $10.00 Price Target at Scotiabank

Kura Oncology (NASDAQ:KURA) had its price objective lowered by Scotiabank from $18.00 to $10.00 in a research note published on Wednesday,Benzinga reports. The brokerage currently has a sector perform rating on the stock.

Several other analysts have also issued reports on the stock. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday, November 20th. Bank of America lowered their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. Jefferies Financial Group reduced their price target on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Finally, JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.38.

Kura Oncology Stock Performance

Shares of KURA opened at $7.32 on Wednesday. Kura Oncology has a 1 year low of $7.18 and a 1 year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock’s fifty day moving average price is $11.75 and its two-hundred day moving average price is $16.95. The firm has a market cap of $569.23 million, a PE ratio of -3.10 and a beta of 0.81.

Hedge Funds Weigh In On Kura Oncology

A number of large investors have recently modified their holdings of KURA. nVerses Capital LLC bought a new position in Kura Oncology during the third quarter valued at approximately $25,000. Point72 DIFC Ltd bought a new position in shares of Kura Oncology during the 3rd quarter valued at $146,000. Quarry LP purchased a new position in Kura Oncology in the 2nd quarter worth $196,000. Erste Asset Management GmbH bought a new stake in Kura Oncology in the third quarter worth $215,000. Finally, Bellevue Group AG boosted its position in Kura Oncology by 36.0% during the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.